Functional Technologies Announces Internal Promotion of Chief Technology and Innovations Officer and Board Changes

Functional Technologies Corp. (TSX VENTURE:FEB)(OTCQX:FEBTF) (the "Company") is
pleased to announce the promotion of Dr. John Husnik to Chief Technology and
Innovations Officer (CTIO), from his current position as Senior Scientist at the
Company; and the appointment of Richard Sherman, JD to the position of Chairman
of the Board of Directors. 


A director of the Company since May 2011 and prior to that a valued Advisory
Board member, Mr. Sherman possesses a wealth of corporate experience, including
in the life science sectors, both as legal counsel and as a principal
structuring joint ventures, licensing agreements and partnerships, and mergers
and acquisitions. He spent more than a decade as Deputy General Counsel of
SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the
Philadelphia law firm of Pepper Hamilton LLP, and was founder and managing
officer of QED Technologies, Inc., a life science business consulting firm later
acquired by The Omnicom Group in New York. He currently maintains an independent
consulting practice and is a principal in a private SBIC investment fund, CIP
Capital, L.P., as well as a Venture Partner of venture funds SCP Private Equity
Partners and SCP/Vitalife II. Mr. Sherman has served on the Board of Directors
of a number of for-profit companies, including CytoMed, Inc., Hawaii Biotech,
Inc., IBAH, Inc.; Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and
Sparta Pharmaceuticals, Inc. and was Chairman of the Board of Directors of
Biophage, Inc. His non-profit and charitable activities have included services
on the Boards of the Pennsylvania Biotechnology Association, the Delaware Valley
Chapter of the American Corporate Counsel Association (where he also served as
President of the chapter), the American Music Theater Festival (also serving as
President), The Sbarro Health Research Organization, the Hawaii Venture Capital
Association, and the Hawaii Science and Technology Council. He has also served
as a member of the investment advisory committee of the Ben Franklin Technology
Center, the Executive Board of the START Technology Partnership, a consortium of
Delaware Valley universities, The Technology Advisory Board for Children's
Hospital of Philadelphia, and the Advisory Board of the University of Hawaii
Medical School. Mr. Sherman graduated magna cum laude from the University of
Nebraska in 1968, and as a Root-Tilden Scholar at the New York University School
of Law, where he received his Juris Doctor in 1971. 


"Given the potential global impact and multiple commercial opportunities
associated with the Company's technology platforms, I look forward to playing a
greater and active role in supporting Functional Technologies' continued growth
and progress as Chairman of the Board of Directors," said Mr. Sherman. 


With his appointment, Dr. John Husnik will be responsible for Functional
Technologies' existing core platforms as well as new innovations, utilizing his
experience in driving R&D assets from bench to commercialization. He will
continue to lead the Company's food science research teams in advancing,
expanding and testing its proprietary technologies, protocols associated with
industry partner (e.g. large food companies)-driven collaborations, and
optimizing as well as extending existing product portfolios. These activities
have and will continue to be facilitated by Dr. Husnik's strong scientific
background over 18 years, including extensive experience encompassing a variety
of techniques associated with classical strain improvement as well as novel and
innovative solutions that enhance native traits of yeasts and other
industry-relevant microorganisms. 


Working with scientists from some of the world's leading institutions, coupled
with the Company's own experience in research and innovation, have allowed Dr.
Husnik to make profound contributions to the creation of the Company's
proprietary core assets, including the cultivation and advancement of Functional
Technologies' core yeast platforms that provide superior functionality and
solutions to critical problems in global food and beverage sectors. He is
credited with helping Functional Technologies innovate and develop the Company's
lead technology platform, the acrylamide-preventing yeasts. Dr. Husnik received
his PhD from the University of British Columbia and his MSc as well as BSc from
the University of Guelph. 


Dr. Husnik said of his appointment "During my time at Functional Technologies, I
have come to appreciate how this Company strives to provide novel and pivotal
platforms to advance the betterment of human health and/or offer valuable
processing solutions via industrial techniques. I am pleased to be able to
continue my efforts to assist the Company in advancing these goals. This
appointment enables me to combine my experience in microbiology, molecular
biology and food science with a broader scientific perspective on innovative
technologies to help create and cultivate meaningful products for the food and
beverage industries." 


The Company also reports that Mr. Howard Louie has stepped down from the Board
of Directors, enabling him to concentrate his efforts as the Company's Chief
Business Development Officer given the intensifying demands associated with both
of Functional Technologies' lead technologies, which are experiencing
significant growth and attention from multinational food and beverage
corporations. "I am grateful for having had the opportunity to serve on the
board of this fine organization for over twelve years. However, with the
considerable increasing activities on the Company's business development front
in the past year, I look forward to now being able to focus ahead on the
successful execution of these many initiatives," said Mr. Louie. The Company's
Board of Directors thanks Mr. Louie for his years of service to the board and
looks forward to his continued contribution to the commercial achievements of
the Company.


The Board of Directors

About Functional Technologies Corp. 

Functional Technologies develops and commercializes proprietary, advanced
yeast-based solutions to significant challenges in the food, beverage and
healthcare industries. The Company's platform improves the performance of innate
yeast functions, and prevents the formation of naturally occurring toxins and
contaminants that either affect final product quality or are classified by the
World Health Organization ("WHO") as probable human carcinogens. Functional
Technologies' lead technologies include yeasts that prevent and reduce the
formation of foul-smelling hydrogen sulphide (H2S) and the WHO classified
probable carcinogen, acrylamide - both by-products of food and beverage
processing. These contaminants are found in many commonly consumed items, such
as fermented food products and alcoholic beverages, and baked and fried foods.
For more information, please visit our website at www.functionaltechcorp.com.